APA (7th ed.) Citation

Alice B. Gottlieb, Atul Deodhar, Iain B. Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, . . . Mark Lebwohl. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Medical Journals Sweden.

Chicago Style (17th ed.) Citation

Alice B. Gottlieb, et al. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Medical Journals Sweden, 2022.

MLA (9th ed.) Citation

Alice B. Gottlieb, et al. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Medical Journals Sweden, 2022.